Drug Name | Payload/MOA/Target | Indication | Rights | Development Stage | ||||
---|---|---|---|---|---|---|---|---|
Pre-clinical | IND | Phase I | Phase II | Phase III |
Drug Name | Payload/MOA/Target | Indication | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
QHL-108 (Legubicin) |
Doxorubicin | Soft Tissue Sarcoma | Global | |||||
---|---|---|---|---|---|---|---|---|
Lung Adenocarcinoma | Global | |||||||
Solid Tumor | Global |
QHL-236 (Legutaxel) |
Paclitaxel | Gastric Carcinoma | Global | |||||
---|---|---|---|---|---|---|---|---|
Solid Tumor | Global |
QHL-339 | Platinum | Solid Tumor | Global |
---|
QHL-1618 | TMEA-Dxd | Solid Tumor | Ex-Greater China |
---|
Drug Name | Payload/MOA/Target | Indication | Rights | Development Stage | ||||
---|---|---|---|---|---|---|---|---|
Pre-clinical | IND | Phase I | Phase II | Phase III |
Drug Name | Payload/MOA/Target | Indication | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
IMD-101 | IL-2 | Bladder Carcinoma | Global | |||||
---|---|---|---|---|---|---|---|---|
Solid Tumor | Global |
IMD-303 | CTLA-4 | Solid Tumor | Global |
---|
IMD-1005 | CD47 | Solid Tumor | Global |
---|
IMD-511 | HER2-CD3 | HER2-positive Breast Cancer | Global | |||||
---|---|---|---|---|---|---|---|---|
HER2-positive Gastric Cancer | Global |
IMD-917 | DLL3-CD3 | Solid Tumor | Global |
---|
IMD-1618 | CLDN6-CD3 | Solid Tumor | Global |
---|
IMD-605 | GCC-CD3 | Solid Tumor | Global |
---|
Drug Name | Payload/MOA/Target | Indication | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
IMD-2101 | Her2 (ADC) | Solid Tumor | Global |
---|
IMD-2109 | PD-L1 (ADC) | Solid Tumor | Global |
---|
IMD-2316 | DLL3 (ADC) | Solid Tumor | Global |
---|
IMD-2113 | EGFR-TROP2 (ADC) | Solid Tumor | Global |
---|
IMD-2128 | EGFR-cMET (ADC) | Solid Tumor | Global |
---|
IMD-2206 | LY6G6D (ADC) | Solid Tumor | Global |
---|
IMD-2329 | DLL3-B7H3 (ADC) | Solid Tumor | Global |
---|
IMD-2408 | CCR8 (ADC) | Solid Tumor | Global |
---|
IMD-2503 | STTR2 (ADC) | Solid Tumor | Global |
---|
IMD-2509 | STTR2-B7H3 (ADC) | Solid Tumor | Global |
---|
IMD-2739 | GCC (ADC) | Solid Tumor | Global |
---|
IMD-3236 | B7H3 (ADC) | Solid Tumor | Global |
---|
Product (Partners) | Molecule | Rights | Development Stage | ||||
---|---|---|---|---|---|---|---|
Pre-clinical | IND | Phase I | Phase II | Phase III |
Product (Partners) | Molecule | Rights | Pre-clinical | IND | Phase I | Phase II | Phase III |
I-MAB
|
Confidential | Global |
Confidential
|
---|
Anglikang Pharmaceutical
|
QHL-1618 TMEA-Dxd | Greater China |
---|
Partner |
TMEA-ICE | Global |
---|
Partner |
TMEAbody | Global |
---|
Partner |
TMEA-SMDC | Global |
---|